热门资讯> 正文
ImmuCell任命Olivier te Boekhorst为首席执行官
2025-09-30 04:13
- 伊芙美尔医疗(ICCC) 0
- 塞拉尼斯(CE) 0
- 纳比特(NA) 0
- ImmuCell (NASDAQ:ICCC) announced that it has selected Olivier te Boekhorst as its next President and CEO, anticipating a start date of November 1, 2025.
- The company said te Boekhorst is currently an operating partner at ARCHIMED, a global investment firm focused on human and animal healthcare industries, and serves as chair of the Board of SeqCenter, where he previously served as CEO. From 2004 to 2022, he held several leadership roles at Maine-based global diagnostics leader IDEXX Laboratories.
- ICCC -3.04% after hours to $5.914.
- Source: Press Release
More on ImmuCell
- ImmuCell outlines cautious H2 outlook as capacity expansion supports First Defense suite
- Financial information for ImmuCell
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
